Synthesis And Biological Evaluation Of Pyrimidine Bridged Biphenyls As Putative Ligands To Target Parkinson's Disease

Simple item page
dc.contributor.authorBala, Manu
dc.contributor.supervisorKumar, Vinod
dc.date.accessioned2018-08-31T04:13:49Z
dc.date.accessioned2024-08-13T11:24:42Z
dc.date.available2018-08-31T04:13:49Z
dc.date.available2024-08-13T11:24:42Z
dc.date.issued2018
dc.description.abstractMAO inhibitors have been explored as therapeutic agents for the treatment or management of PD. A series of 2,4,6-trisubstituted pyrimidine derivatives incorporating a propargyl moiety were synthesized and screened for their MAO inhibition potential using Amplex® Red assay. All the compounds showed good inhibitory activity for MAO-B. The structure-activity relationship profile has been developed with number of electron releasing and electron withdrawing substituents attached to the pyrimidine nucleus. MV7 was found to be the most potent MAO-B inhibitor with IC50 value of 0.44 ± 0.02 ?M. From molecular docking studies, it was found that compounds fit well in the active site of MAO-B isoform near FAD cofactor. Thus, the active compound MV7 obtained in this series can act as promising lead for the development of effective and potent MAO-B inhibitor for the treatment of Parkinson's disease.en_US
dc.identifier.accessionnoT00755
dc.identifier.citationBala, Manu (2018) Synthesis And Biological Evaluation Of Pyrimidine Bridged Biphenyls As Putative Ligands To Target Parkinson's Disease.en_US
dc.identifier.urihttp://10.2.3.109/handle/32116/1941
dc.language.isoen_USen_US
dc.publisherCentral University of Punjaben_US
dc.titleSynthesis And Biological Evaluation Of Pyrimidine Bridged Biphenyls As Putative Ligands To Target Parkinson's Diseaseen_US
dc.typeMaster Dissertationen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
T00755.pdf
Size:
5.19 MB
Format:
Adobe Portable Document Format
Download

Collections

Pharmaceutical Sciences and Natural Products - Master Dissertation
Master's Dissertations